Article Information
vol. 28 no. 153
PubMed
Published By
Print ISSN
Online ISSN
History
- Received February 27, 2019
- Accepted May 16, 2019
- Published online September 4, 2019.
Copyright & Usage
Copyright ©ERS 2019. http://creativecommons.org/licenses/by-nc/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Author Information
- Vivien Somogyi1,2,
- Nazia Chaudhuri3,
- Sebastiano Emanuele Torrisi1,4,
- Nicolas Kahn1,
- Veronika Müller2 and
- Michael Kreuter1⇑
- 1Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany
- 2Dept of Pulmonology, Semmelweis University, Budapest, Hungary
- 3Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester, UK
- 4Regional Referral Centre for Rare Lung Diseases, University Hospital “Policlinico”, Dept of Clinical and Experimental Medicine, University of Catania, Catania, Italy
- Michael Kreuter, Center for Interstitial and Rare Lung Diseases, Thoraxklinik, University of Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany. E-mail: kreuter{at}uni-heidelberg.de
Article usage
Altmetrics
Vol 28 Issue 153
Table of Contents
The therapy of idiopathic pulmonary fibrosis: what is next?
Jump To
- Article
- Abstract
- Abstract
- Introduction
- ABCDE and future approaches in IPF
- Biomarkers guiding therapy
- New approaches in drug treatment in IPF
- Developments in lung transplantation
- Pulmonary rehabilitation
- New ways to approach palliative intervention
- Treatment of comorbidities
- Urgent unmet need for AE-IPF
- Conclusions
- Footnotes
- References
- Figures & Data
- Info & Metrics